Insmed (INSM) Receivables (2010 - 2026)

Insmed has reported Receivables for 11 years, with the latest figure at $215.3 million in Q2 2026.

• On a quarterly basis, Receivables rose 291.27% year-over-year to $215.3 million in Q2 2026; TTM through Jun 2026 was $215.3 million, a 291.27% increase from a year earlier, with the FY2025 full-year figure at $140.9 million, up 170.82% from the prior year.
• Receivables was $215.3 million for Q2 2026 at Insmed, up from $178.6 million in the prior quarter.
• The five-year high for Receivables was $215.3 million in Q2 2026, with the low at $25.7 million in Q1 2022.
• Average Receivables over 5 years is $62.5 million, with a median of $40.7 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2026: Receivables rose 4.97% in 2023, then jumped 291.27% in 2026.
• Over 5 years, Receivables stood at $29.7 million in 2022, then jumped by 38.62% to $41.2 million in 2023, then grew by 26.28% to $52.0 million in 2024, then jumped by 170.82% to $140.9 million in 2025, then jumped by 52.87% to $215.3 million in 2026.
• The last three Receivables figures came in at $215.3 million (Q2 2026), $178.6 million (Q1 2026), and $140.9 million (Q4 2025), per Business Quant data.